Franz-Werner Haas, CureVac CEO

On the heels of a snap $1B raise, Cure­Vac out­lines plans to seek emer­gency OK for Covid-19 vac­cine -- shares rock­et up

Cure­Vac is go­ing from be­ing one of the qui­etest play­ers in the race to de­vel­op a new vac­cine to fight the worst pub­lic health cri­sis in a cen­tu­ry to a chal­lenger for the multi­bil­lion-dol­lar mar­ket that awaits the first vac­cines to make it over the fin­ish line. Typ­i­cal­ly low-key at a time of brash com­ments and in­cred­i­bly am­bi­tious de­vel­op­ment time­lines from the lead­ers, Cure­Vac now is jump­ing straight in­to the spot­light.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.